A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease

• Status: Terminated
• Trial end date: 2018-01-12
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Prilenia; Teva Branded Pharmaceutical Products, R&D Inc.

Criteria

Inclusion Criteria:

• Pride HD completion within the last 6 months, including 2 week follow up period or patients who transitioned from the Open HART study or patients who complete future safety and efficacy clinical trials of pridopidine. In addition, patients who have already completed their defined study period under Open PRIDE HD global or local amendments and have discontinued treatment with pridopidine will be allowed to re enter the Open PRIDE HD study.

• Women of child bearing potential or male participants: Adequate contraception and birth control

• Good general health

• other criteria apply, please contact the investigator for more information

Exclusion Criteria:

• Similar baseline criteria for ECG, vital signs, cardiovascular system, and renal function to PRIDE HD;

• Similar concomitant medication restrictions to PRIDE HD.

• other criteria apply, please contact the investigator for more information